Eptinezumab News
Eptinezumab currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Eptinezumab with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
- Evidence level: L5
- Predicted indications (20):
- migraine with brainstem aura (99.9%)
- migraine disorder (99.9%)
- migraine with or without aura, susceptibility to (99.3%)
- atrophoderma vermiculata (99.0%)
- ulerythema ophryogenesis (98.6%)
- heparin cofactor 2 deficiency (96.8%)
- antithrombin deficiency type 2 (96.2%)
- factor 5 excess with spontaneous thrombosis (96.1%)
- thrombophilia (94.2%)
- amenorrhea (disease) (92.4%)
- sciatic neuropathy (89.9%)
- hemorrhagic disease of newborn (81.3%)
- severe nonproliferative diabetic retinopathy (67.7%)
- hyperemesis gravidarum (disease) (64.3%)
- hyperparathyroidism, primary, caused by water clear cell hyperplasia (60.2%)
- omphalocele (disease) (59.8%)
- prekallikrein deficiency (59.4%)
- sudden arrhythmia death syndrome (59.4%)
- Coronavinae infectious disease (58.8%)
- tibial adamantinoma (58.5%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.